Tradewinds Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Tradewinds Capital Management’s Portfolio CLDI Stock Details CLDI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7	Hold	6	–	–	﹤0.01%	704
2026 Q2	$18	Hold	6	–	–	﹤0.01%	701
2026 Q1	$25	Hold	6	–	–	﹤0.01%	700
2025 Q4	$119	Hold	6	–	–	﹤0.01%	650
2025 Q3	$154	Buy	6 +1	+20%	+$68	﹤0.01%	640
2025 Q2	$230	Hold	5	–	–	﹤0.01%	593
2025 Q1	$567	Hold	5	–	–	﹤0.01%	574
2024 Q4	$1.15K	Buy	+5	New	+$1.5K	﹤0.01%	535

Other funds holding CLDI

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Tradewinds Capital Management's CLDI Position: Q3 2026 in Review

Tradewinds Capital Management held its Calidi Biotherapeutics (CLDI) position steady in Q3 2026 at 6 shares worth $7. The position accounts for ﹤0.01% of the portfolio, ranked #704.

Tradewinds Capital Management first reported a position in CLDI in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.15K in Q4 2024. 3 funds tracked by Wall St. Rank hold CLDI as of Q3 2026.

Tradewinds Capital Management held 6 shares of Calidi Biotherapeutics worth $7 as of Q3 2026.
Tradewinds Capital Management left its Calidi Biotherapeutics share count unchanged in Q3 2026.
Calidi Biotherapeutics made up ﹤0.01% of Tradewinds Capital Management's portfolio in Q3 2026, its #704 holding.
Tradewinds Capital Management first reported a position in Calidi Biotherapeutics in Q4 2024 and has held it in 8 quarters since.
Tradewinds Capital Management's Calidi Biotherapeutics position peaked at $1.15K in Q4 2024.
3 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2026.

Based on Tradewinds Capital Management's 13F filing for Q3 2026, filed 23 Oct 2026.